nebivolol ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
beta-adrenoreceptor antagonists 1887 118457-14-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nebivolol
  • nebivolol hydrochloride
  • vasoxen
  • bystolic
  • nebivolol HCl
A cardioselective ADRENERGIC BETA-1 RECEPTOR ANTAGONIST (beta-blocker) that functions as a VASODILATOR through the endothelial L-arginine/ NITRIC OXIDE system. It is used to manage HYPERTENSION and chronic HEART FAILURE in elderly patients.
  • Molecular weight: 405.44
  • Formula: C22H25F2NO4
  • CLOGP: 3.50
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 3
  • TPSA: 70.95
  • ALOGS: -4
  • ROTB: 6

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
5 mg O

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.35 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 50 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 11 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 14 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.02 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 10 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 17, 2007 FDA FOREST LABS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Bradycardia 179.12 11.34 199 27837 64227 50512861
Acute kidney injury 171.52 11.34 385 27651 227673 50349415
Hyponatraemia 126.33 11.34 206 27830 95933 50481155
Hypertensive crisis 126.30 11.34 83 27953 13071 50564017
Hypotension 86.75 11.34 307 27729 235162 50341926
Drug interaction 82.94 11.34 271 27765 199350 50377738
Anaemia 78.72 11.34 312 27724 252144 50324944
Systemic lupus erythematosus 65.24 11.34 3 28033 140619 50436469
Joint swelling 62.30 11.34 29 28007 245257 50331831
Acute motor-sensory axonal neuropathy 57.89 11.34 16 28020 272 50576816
Fall 56.87 11.34 348 27688 334584 50242504
Lip oedema 53.89 11.34 29 28007 3164 50573924
Synovitis 53.33 11.34 4 28032 123861 50453227
Treatment failure 52.62 11.34 7 28029 137630 50439458
Syncope 51.22 11.34 149 27887 102853 50474235
Traumatic coma 50.86 11.34 11 28025 61 50577027
Pain 49.92 11.34 160 27876 578743 49998345
Maternal exposure during pregnancy 48.80 11.34 14 28022 159764 50417324
Rheumatoid arthritis 45.47 11.34 28 28008 202522 50374566
Arthropathy 44.39 11.34 16 28020 157890 50419198
Glossodynia 43.88 11.34 6 28030 115563 50461525
Ischaemic stroke 43.80 11.34 49 27987 15899 50561189
Drug ineffective 43.22 11.34 272 27764 819061 49758027
Hyperkalaemia 40.32 11.34 85 27951 48004 50529084
Cardiac failure 39.73 11.34 112 27924 75928 50501160
Angina pectoris 39.72 11.34 60 27976 26128 50550960
Product prescribing error 39.11 11.34 53 27983 20908 50556180
Therapeutic product effect decreased 37.87 11.34 14 28022 136036 50441052
Dyspnoea 37.00 11.34 464 27572 547144 50029944
Atrial fibrillation 35.94 11.34 131 27905 101614 50475474
Melaena 35.81 11.34 58 27978 26806 50550282
General physical health deterioration 35.75 11.34 165 27871 142269 50434819
Sopor 35.18 11.34 49 27987 19830 50557258
Rhabdomyolysis 35.08 11.34 71 27965 38956 50538132
Cerebellar ataxia 33.53 11.34 14 28022 864 50576224
Infusion related reaction 33.35 11.34 27 28009 169530 50407558
Vertigo 32.81 11.34 82 27954 51750 50525338
Exposure during pregnancy 32.77 11.34 13 28023 121002 50456086
Hepatocellular injury 31.87 11.34 54 27982 25893 50551195
Contraindicated product administered 30.20 11.34 23 28013 148935 50428153
Hypomagnesaemia 29.52 11.34 49 27987 23107 50553981
Hypokalaemia 29.15 11.34 111 27925 87881 50489207
Swelling 27.48 11.34 43 27993 200829 50376259
Drug hypersensitivity 27.09 11.34 62 27974 250948 50326140
Erythrosis 25.95 11.34 6 28030 47 50577041
Systemic infection 25.87 11.34 16 28020 2267 50574821
Miosis 25.74 11.34 24 28012 6286 50570802
Primary hyperaldosteronism 25.41 11.34 6 28030 52 50577036
Abdominal discomfort 25.16 11.34 57 27979 231584 50345504
Tongue oedema 24.74 11.34 19 28017 3820 50573268
Retroperitoneal haematoma 23.73 11.34 16 28020 2627 50574461
Chronic pigmented purpura 23.06 11.34 6 28030 80 50577008
Asthenia 23.04 11.34 274 27762 318768 50258320
Arthralgia 22.81 11.34 146 27890 438556 50138532
Resting tremor 22.54 11.34 10 28026 716 50576372
Walking disability 22.52 11.34 12 28024 1284 50575804
Renin decreased 22.11 11.34 6 28030 95 50576993
Infection 21.82 11.34 39 27997 172915 50404173
Arrhythmia 21.58 11.34 53 27983 33079 50544009
Angioedema 21.16 11.34 57 27979 37619 50539469
Drug intolerance 20.62 11.34 58 27978 219046 50358042
Pericarditis 20.42 11.34 9 28027 78680 50498408
Cholestasis 20.25 11.34 44 27992 25357 50551731
Disorientation 20.25 11.34 54 27982 35430 50541658
Arterial spasm 19.70 11.34 5 28031 60 50577028
Haematoma muscle 19.35 11.34 9 28027 719 50576369
Agranulocytosis 19.28 11.34 39 27997 21382 50555706
Blood aldosterone increased 19.06 11.34 6 28030 163 50576925
Peripheral ischaemia 18.88 11.34 17 28019 4259 50572829
Sprue-like enteropathy 18.84 11.34 8 28028 515 50576573
Cerebral haematoma 18.76 11.34 15 28021 3196 50573892
Adenocarcinoma metastatic 18.67 11.34 5 28031 75 50577013
Hypoosmolar state 18.59 11.34 6 28030 177 50576911
Aeromonas infection 18.55 11.34 5 28031 77 50577011
Oedema peripheral 18.41 11.34 150 27886 157811 50419277
Presyncope 18.25 11.34 41 27995 24157 50552931
Rash 18.21 11.34 155 27881 437316 50139772
Discomfort 18.09 11.34 20 28016 108360 50468728
Urine output increased 18.06 11.34 10 28026 1154 50575934
Hemiparesis 17.45 11.34 36 28000 20012 50557076
Blood loss anaemia 17.38 11.34 22 28014 8117 50568971
Nocturia 17.33 11.34 20 28016 6710 50570378
Drop attacks 17.03 11.34 8 28028 654 50576434
Haematoma 16.97 11.34 46 27990 30464 50546624
Product use issue 16.86 11.34 36 28000 149439 50427649
Rectal haemorrhage 16.54 11.34 53 27983 38505 50538583
Cerebral salt-wasting syndrome 16.25 11.34 4 28032 42 50577046
Elephantiasis 16.20 11.34 3 28033 6 50577082
Hypersensitivity pneumonitis 16.09 11.34 12 28024 2310 50574778
Wound 16.08 11.34 21 28015 105773 50471315
Dry gangrene 16.04 11.34 7 28029 482 50576606
Hypoglycaemia 15.65 11.34 65 27971 53516 50523572
Platelet disorder 15.61 11.34 10 28026 1507 50575581
Metabolic acidosis 15.43 11.34 52 27984 38773 50538315
Nasopharyngitis 15.39 11.34 55 27981 192872 50384216
Diffuse large B-cell lymphoma stage II 15.26 11.34 4 28032 55 50577033
Wrong schedule 15.22 11.34 5 28031 156 50576932
Electrolyte imbalance 15.15 11.34 31 28005 17138 50559950
Microcytic anaemia 15.09 11.34 13 28023 3071 50574017
Orthostatic hypotension 14.97 11.34 43 27993 29438 50547650
Hypersensitivity 14.84 11.34 65 27971 215096 50361992
Anuria 14.61 11.34 24 28012 11220 50565868
Musculoskeletal stiffness 14.44 11.34 31 28005 128450 50448638
Nasal mucosal erosion 14.36 11.34 4 28032 70 50577018
Vascular encephalopathy 14.16 11.34 6 28030 384 50576704
Loss of personal independence in daily activities 13.95 11.34 11 28025 70039 50507049
Renal function test abnormal 13.92 11.34 12 28024 2837 50574251
Impaired healing 13.85 11.34 11 28025 69775 50507313
Hyperammonaemia 13.81 11.34 15 28021 4709 50572379
Intraventricular haemorrhage 13.71 11.34 10 28026 1860 50575228
Sinus bradycardia 13.07 11.34 25 28011 13158 50563930
Diaphragmatic disorder 12.98 11.34 6 28030 473 50576615
Intra-abdominal haematoma 12.97 11.34 9 28027 1548 50575540
Renal failure 12.82 11.34 102 27934 106531 50470557
Product measured potency issue 12.73 11.34 4 28032 108 50576980
Hypovolaemic shock 12.66 11.34 15 28021 5173 50571915
Thrombocytopenia 12.65 11.34 117 27919 127556 50449532
Cardiac failure acute 12.65 11.34 19 28017 8231 50568857
Disease progression 12.64 11.34 21 28015 95845 50481243
Haemorrhagic stroke 12.57 11.34 15 28021 5213 50571875
Ductal adenocarcinoma of pancreas 12.49 11.34 4 28032 115 50576973
Peripheral artery stenosis 12.41 11.34 6 28030 523 50576565
Cerebral haemorrhage 12.35 11.34 38 27998 27014 50550074
Prescription drug used without a prescription 12.26 11.34 9 28027 1691 50575397
Blood pressure increased 12.20 11.34 120 27916 133012 50444076
Gastrointestinal disorder 12.17 11.34 21 28015 94435 50482653
Action tremor 12.15 11.34 5 28031 297 50576791
Arterial thrombosis 12.11 11.34 8 28028 1269 50575819
Mucosal hyperaemia 12.06 11.34 3 28033 33 50577055
Withdrawal hypertension 12.02 11.34 4 28032 130 50576958
Toxic skin eruption 11.98 11.34 22 28014 11229 50565859
Psychotic behaviour 11.95 11.34 6 28030 567 50576521
Labelled drug-drug interaction medication error 11.81 11.34 21 28015 10456 50566632
Coronavirus infection 11.68 11.34 11 28025 2918 50574170
Hypocalcaemia 11.63 11.34 37 27999 26779 50550309
Haemodynamic instability 11.62 11.34 18 28018 8006 50569082
International normalised ratio increased 11.56 11.34 51 27985 43101 50533987
Diarrhoea 11.56 11.34 416 27620 588060 49989028
Sinusitis 11.47 11.34 52 27984 170506 50406582
Hypotonia 11.44 11.34 18 28018 8116 50568972
Attention deficit hyperactivity disorder 11.40 11.34 10 28026 2419 50574669
Disorganised speech 11.37 11.34 7 28029 984 50576104

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 132.50 11.60 473 22097 264794 29287163
Hyperkalaemia 120.51 11.60 188 22382 61204 29490753
Lactic acidosis 80.35 11.60 107 22463 30140 29521817
Bradycardia 71.57 11.60 156 22414 65473 29486484
Hypoparathyroidism 45.00 11.60 16 22554 458 29551499
Toxicity to various agents 43.61 11.60 41 22529 173620 29378337
Syncope 38.52 11.60 143 22427 81228 29470729
Hypokalaemia 38.26 11.60 104 22466 50099 29501858
Hypotension 38.00 11.60 266 22304 194088 29357869
Cerebral haematoma 35.35 11.60 28 22542 4268 29547689
Hypertensive crisis 34.58 11.60 36 22534 7812 29544145
Death 32.91 11.60 142 22428 341942 29210015
Renal artery thrombosis 32.01 11.60 11 22559 284 29551673
Burnout syndrome 30.52 11.60 9 22561 139 29551818
Shock haemorrhagic 30.42 11.60 37 22533 9514 29542443
Product monitoring error 30.21 11.60 21 22549 2624 29549333
Ischaemic stroke 28.64 11.60 47 22523 15930 29536027
Pemphigoid 28.53 11.60 32 22538 7549 29544408
Anaemia 28.25 11.60 255 22315 200696 29351261
Cerebellar ischaemia 27.34 11.60 8 22562 120 29551837
Presyncope 27.06 11.60 46 22524 16043 29535914
Blood lactic acid 26.61 11.60 10 22560 336 29551621
Renal failure 26.55 11.60 168 22402 118431 29433526
Cutaneous lupus erythematosus 25.43 11.60 12 22558 716 29551241
Cerebellar syndrome 25.40 11.60 17 22553 1997 29549960
Intercapillary glomerulosclerosis 24.88 11.60 6 22564 40 29551917
Cardiac failure 24.85 11.60 123 22447 79164 29472793
Coma uraemic 24.76 11.60 6 22564 41 29551916
Fungal endocarditis 24.60 11.60 9 22561 280 29551677
Febrile neutropenia 24.25 11.60 30 22540 112210 29439747
Melaena 24.16 11.60 65 22505 31111 29520846
Vitamin B12 decreased 24.01 11.60 13 22557 1039 29550918
Brief psychotic disorder with marked stressors 23.95 11.60 8 22562 189 29551768
Vascular purpura 23.07 11.60 14 22556 1389 29550568
Laryngeal cancer metastatic 22.82 11.60 6 22564 59 29551898
Vertigo 22.70 11.60 51 22519 21810 29530147
Angina pectoris 22.52 11.60 59 22511 27791 29524166
Decreased ventricular preload 22.48 11.60 5 22565 22 29551935
Cholestasis 22.45 11.60 53 22517 23409 29528548
Renal ischaemia 22.36 11.60 10 22560 527 29551430
Cardiac failure chronic 22.15 11.60 26 22544 6441 29545516
Labelled drug-drug interaction medication error 22.10 11.60 36 22534 12123 29539834
Hepatocellular injury 21.43 11.60 49 22521 21194 29530763
Bronchitis bacterial 20.42 11.60 10 22560 648 29551309
White blood cell count decreased 19.38 11.60 21 22549 83341 29468616
Enzyme induction 19.13 11.60 5 22565 48 29551909
Potentiating drug interaction 18.91 11.60 20 22550 4418 29547539
Platelet count decreased 18.66 11.60 32 22538 104640 29447317
Agoraphobia 18.63 11.60 7 22563 235 29551722
Infective exacerbation of chronic obstructive airways disease 18.61 11.60 13 22557 1637 29550320
Left ventricle outflow tract obstruction 18.40 11.60 6 22564 131 29551826
Neurosis 17.95 11.60 6 22564 142 29551815
Hepatic function abnormal 17.92 11.60 4 22566 39255 29512702
Acute coronary syndrome 17.84 11.60 33 22537 12292 29539665
Carbohydrate metabolism disorder 17.56 11.60 4 22566 20 29551937
Retinal disorder 17.47 11.60 10 22560 890 29551067
Metabolic alkalosis 16.97 11.60 11 22559 1225 29550732
Anticoagulation drug level increased 16.82 11.60 8 22562 486 29551471
Dialysis device insertion 16.68 11.60 4 22566 26 29551931
Haematoma 16.60 11.60 47 22523 23165 29528792
Transient ischaemic attack 16.52 11.60 47 22523 23223 29528734
Normocytic anaemia 16.42 11.60 13 22557 1979 29549978
Electrocardiogram T wave abnormal 16.07 11.60 11 22559 1340 29550617
Drug interaction 16.04 11.60 225 22345 197160 29354797
Coma 15.94 11.60 66 22504 39384 29512573
Blood creatine phosphokinase MB increased 15.64 11.60 12 22558 1745 29550212
Neutrophil count decreased 15.36 11.60 7 22563 43560 29508397
Hypomagnesaemia 15.15 11.60 38 22532 17430 29534527
Perioral dermatitis 15.01 11.60 5 22565 117 29551840
Disseminated aspergillosis 14.89 11.60 7 22563 414 29551543
Diabetic nephropathy 14.84 11.60 12 22558 1883 29550074
Haemorrhagic erosive gastritis 14.78 11.60 5 22565 123 29551834
Hypertensive nephropathy 14.72 11.60 7 22563 425 29551532
Drug abuse 14.62 11.60 24 22546 79859 29472098
Atrial tachycardia 14.59 11.60 12 22558 1929 29550028
Traumatic haemothorax 14.59 11.60 6 22564 257 29551700
Brain natriuretic peptide increased 14.48 11.60 17 22553 4213 29547744
Funguria 13.93 11.60 4 22566 56 29551901
Dermatosis 13.85 11.60 6 22564 293 29551664
Interstitial lung disease 13.67 11.60 83 22487 57635 29494322
Extrasystoles 13.65 11.60 15 22555 3459 29548498
Carcinogenicity 13.61 11.60 4 22566 61 29551896
Congenital inguinal hernia 13.59 11.60 5 22565 158 29551799
Palpitations 13.53 11.60 55 22515 32549 29519408
Orthostatic hypotension 13.51 11.60 43 22527 22586 29529371
Haemoglobinaemia 13.51 11.60 5 22565 161 29551796
Electrocardiogram QT prolonged 13.47 11.60 59 22511 36078 29515879
Oral lichen planus 13.36 11.60 5 22565 166 29551791
Cardioactive drug level decreased 13.15 11.60 4 22566 69 29551888
Anuria 13.13 11.60 25 22545 9516 29542441
Epilepsy 12.86 11.60 37 22533 18395 29533562
Gingival discomfort 12.84 11.60 4 22566 75 29551882
Albumin urine present 12.58 11.60 6 22564 367 29551590
Pain 12.55 11.60 78 22492 171354 29380603
IIIrd nerve disorder 12.24 11.60 4 22566 88 29551869
Acute pulmonary oedema 12.22 11.60 20 22550 6759 29545198
Malpositioned teeth 12.08 11.60 3 22567 23 29551934
Tachyarrhythmia 11.98 11.60 13 22557 2956 29549001
Pancreatitis acute 11.64 11.60 43 22527 24342 29527615

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 300.69 10.71 824 43163 448416 64006329
Bradycardia 202.41 10.71 320 43667 117899 64336846
Hyperkalaemia 155.75 10.71 261 43726 100868 64353877
Hypertensive crisis 153.28 10.71 115 43872 18133 64436612
Hypotension 104.92 10.71 525 43462 380449 64074296
Anaemia 103.69 10.71 521 43466 378159 64076586
Hyponatraemia 101.52 10.71 275 43712 148064 64306681
Syncope 84.60 10.71 268 43719 157367 64297378
Drug interaction 82.61 10.71 474 43513 361609 64093136
Lactic acidosis 78.33 10.71 146 43841 61264 64393481
Ischaemic stroke 67.64 10.71 91 43896 28944 64425801
Melaena 58.17 10.71 119 43868 53429 64401316
Vertigo 56.99 10.71 125 43862 58886 64395859
Pain 56.08 10.71 192 43795 553319 63901426
Fall 55.64 10.71 479 43508 416347 64038398
Synovitis 52.32 10.71 4 43983 99086 64355659
Cardiac failure 51.92 10.71 203 43784 132170 64322575
Cerebral haematoma 51.01 10.71 41 43946 7144 64447601
Hepatocellular injury 50.88 10.71 102 43885 45133 64409612
Hypokalaemia 49.48 10.71 189 43798 121714 64333031
Acute motor-sensory axonal neuropathy 48.96 10.71 16 43971 396 64454349
Angina pectoris 48.75 10.71 100 43887 44981 64409764
Joint swelling 46.44 10.71 47 43940 215335 64239410
Traumatic coma 45.03 10.71 10 43977 50 64454695
Cholestasis 43.27 10.71 95 43892 44777 64409968
Presyncope 42.96 10.71 82 43905 35007 64419738
Rheumatoid arthritis 42.59 10.71 30 43957 164264 64290481
Toxicity to various agents 41.76 10.71 119 43868 363394 64091351
General physical health deterioration 40.38 10.71 258 43729 204167 64250578
Lip oedema 39.82 10.71 31 43956 5158 64449587
Shock haemorrhagic 39.68 10.71 53 43934 16738 64438007
Treatment failure 39.67 10.71 15 43972 116801 64337944
Infusion related reaction 38.86 10.71 33 43954 164434 64290311
Systemic lupus erythematosus 38.63 10.71 4 43983 77608 64377137
Maternal exposure during pregnancy 38.58 10.71 9 43978 95875 64358870
Drug hypersensitivity 37.86 10.71 65 43922 237750 64216995
Therapeutic product effect decreased 37.23 10.71 16 43971 115335 64339410
Exposure during pregnancy 36.20 10.71 5 43982 77670 64377075
Hypomagnesaemia 35.89 10.71 79 43908 37297 64417448
Arthropathy 35.65 10.71 19 43968 120948 64333797
Haematoma 32.85 10.71 87 43900 46163 64408582
Drug ineffective 32.58 10.71 392 43595 839855 63614890
Dyspnoea 32.53 10.71 678 43309 717996 63736749
Renal failure 32.06 10.71 223 43764 181465 64273280
Labelled drug-drug interaction medication error 31.36 10.71 55 43932 22007 64432738
Pemphigus 30.54 10.71 3 43984 60698 64394047
Hepatic function abnormal 30.30 10.71 4 43983 64309 64390436
Retro-orbital neoplasm 29.52 10.71 7 43980 49 64454696
Anuria 29.22 10.71 49 43938 18915 64435830
Arthralgia 28.87 10.71 180 43807 442080 64012665
Renal artery thrombosis 28.61 10.71 11 43976 442 64454303
Acute coronary syndrome 28.57 10.71 49 43938 19261 64435484
Product monitoring error 28.28 10.71 26 43961 5428 64449317
Atrial fibrillation 26.74 10.71 204 43783 170885 64283860
Cerebellar ataxia 26.45 10.71 16 43971 1767 64452978
Orthostatic hypotension 26.45 10.71 81 43906 46657 64408088
Metabolic acidosis 26.34 10.71 107 43880 70851 64383894
Agranulocytosis 26.23 10.71 71 43916 38158 64416587
Pemphigoid 26.21 10.71 38 43949 12948 64441797
Haemorrhagic stroke 25.99 10.71 33 43954 9918 64444827
Vascular purpura 25.77 10.71 18 43969 2538 64452207
Coma uraemic 25.30 10.71 6 43981 42 64454703
Nasopharyngitis 24.90 10.71 61 43926 196012 64258733
Asthenia 24.89 10.71 420 43567 427624 64027121
Blood lactic acid 24.87 10.71 10 43977 453 64454292
Hypoglycaemia 24.70 10.71 124 43863 89768 64364977
Death 24.06 10.71 212 43775 482493 63972252
Cardiac failure chronic 23.64 10.71 30 43957 9011 64445734
White blood cell count decreased 23.44 10.71 45 43942 157792 64296953
Sopor 23.34 10.71 58 43929 29603 64425142
Intercapillary glomerulosclerosis 23.22 10.71 6 43981 62 64454683
Product prescribing error 22.70 10.71 64 43923 35205 64419540
Brief psychotic disorder with marked stressors 22.33 10.71 8 43979 263 64454482
Infective exacerbation of chronic obstructive airways disease 21.89 10.71 16 43971 2422 64452323
Retroperitoneal haematoma 21.64 10.71 21 43966 4690 64450055
Carbohydrate metabolism disorder 21.61 10.71 5 43982 31 64454714
Interstitial lung disease 21.57 10.71 127 43860 97605 64357140
Blood loss anaemia 21.54 10.71 36 43951 13856 64440889
Hypoparathyroidism 21.51 10.71 11 43976 876 64453869
Cerebral haemorrhage 21.36 10.71 80 43907 51010 64403735
Burnout syndrome 21.33 10.71 8 43979 300 64454445
Decreased ventricular preload 21.21 10.71 5 43982 34 64454711
Musculoskeletal stiffness 21.16 10.71 32 43955 123174 64331571
Hyperlactacidaemia 21.15 10.71 21 43966 4823 64449922
Walking disability 20.95 10.71 14 43973 1837 64452908
Acute pulmonary oedema 20.95 10.71 34 43953 12775 64441970
Glossodynia 20.83 10.71 9 43978 64687 64390058
Erythrosis 20.70 10.71 6 43981 98 64454647
Cutaneous lupus erythematosus 20.53 10.71 16 43971 2666 64452079
Cerebellar syndrome 20.53 10.71 21 43966 4995 64449750
Sinusitis 20.47 10.71 43 43944 145885 64308860
Bronchitis bacterial 20.44 10.71 12 43975 1255 64453490
Renin decreased 20.05 10.71 6 43981 110 64454635
Platelet count decreased 19.89 10.71 54 43933 167657 64287088
Pancreatitis acute 19.52 10.71 69 43918 42786 64411959
Laryngeal cancer metastatic 19.50 10.71 5 43982 50 64454695
Sinus bradycardia 19.33 10.71 46 43941 22847 64431898
Primary hyperaldosteronism 19.07 10.71 6 43981 131 64454614
Neutrophil count decreased 18.83 10.71 15 43972 77181 64377564
Cerebellar ischaemia 18.34 10.71 6 43981 149 64454596
Hypocalcaemia 17.97 10.71 66 43921 41687 64413058
Loss of personal independence in daily activities 17.77 10.71 14 43973 72440 64382305
Contraindicated product administered 17.58 10.71 29 43958 107800 64346945
Arterial thrombosis 17.53 10.71 14 43973 2416 64452329
Fungal endocarditis 17.52 10.71 8 43979 496 64454249
Electrolyte imbalance 17.43 10.71 47 43940 25196 64429549
Chronic pigmented purpura 17.30 10.71 6 43981 179 64454566
Sprue-like enteropathy 17.27 10.71 10 43977 1019 64453726
Jaundice 17.09 10.71 72 43915 48440 64406305
Epistaxis 17.03 10.71 120 43867 98011 64356734
Febrile neutropenia 17.02 10.71 68 43919 187589 64267156
Renal ischaemia 16.80 10.71 10 43977 1073 64453672
Angioedema 16.78 10.71 85 43902 61736 64393009
Helicobacter infection 16.67 10.71 3 43984 38359 64416386
Haematoma muscle 16.63 10.71 12 43975 1781 64452964
Diabetic nephropathy 16.45 10.71 14 43973 2640 64452105
Adenocarcinoma metastatic 16.45 10.71 5 43982 97 64454648
Blood aldosterone increased 16.34 10.71 6 43981 212 64454533
Urine output increased 16.23 10.71 12 43975 1849 64452896
Contraindicated product prescribed 16.11 10.71 10 43977 1157 64453588
Enzyme induction 15.85 10.71 5 43982 110 64454635
Muscle mass 15.77 10.71 7 43980 406 64454339
Drug reaction with eosinophilia and systemic symptoms 15.75 10.71 76 43911 54141 64400604
Pericarditis 15.43 10.71 12 43975 62504 64392241
Abdominal discomfort 15.34 10.71 68 43919 182254 64272491
Haemoglobinaemia 15.29 10.71 6 43981 255 64454490
Intracranial mass 15.23 10.71 12 43975 2031 64452714
Hypoosmolar state 15.22 10.71 6 43981 258 64454487
Fibromyalgia 15.09 10.71 3 43984 35728 64419017
Infection 14.93 10.71 70 43917 184810 64269935
Palpitations 14.89 10.71 122 43865 104366 64350379
Hepatic mass 14.82 10.71 12 43975 2112 64452633
Elephantiasis 14.72 10.71 3 43984 9 64454736
Hypotonia 14.71 10.71 27 43960 11185 64443560
Poisoning deliberate 14.71 10.71 30 43957 13428 64441317
Atrioventricular block 14.61 10.71 28 43959 11987 64442758
Dermatosis 14.42 10.71 7 43980 499 64454246
Disease progression 14.38 10.71 49 43938 141631 64313114
Resting tremor 14.35 10.71 10 43977 1404 64453341
Vitamin B12 decreased 14.19 10.71 13 43974 2702 64452043
Language disorder 14.18 10.71 13 43974 2704 64452041
Dialysis device insertion 14.18 10.71 4 43983 59 64454686
Arterial spasm 14.17 10.71 5 43982 157 64454588
Mobility decreased 14.07 10.71 23 43964 85817 64368928
Systemic infection 14.02 10.71 16 43971 4305 64450440
Oedema peripheral 13.93 10.71 211 43776 210106 64244639
Coronavirus infection 13.91 10.71 18 43969 5512 64449233
Renal impairment 13.88 10.71 147 43840 134870 64319875
Body temperature increased 13.68 10.71 4 43983 36662 64418083
Drug dependence 13.65 10.71 3 43984 33309 64421436
Nasal mucosal erosion 13.54 10.71 4 43983 70 64454675
Brain natriuretic peptide increased 13.50 10.71 21 43966 7612 64447133
Renal function test abnormal 13.38 10.71 15 43972 3959 64450786
Erysipelas 13.37 10.71 23 43964 9058 64445687
Sinus rhythm 13.36 10.71 7 43980 586 64454159
Dermatitis bullous 13.33 10.71 27 43960 12027 64442718
Back pain 13.27 10.71 108 43879 250063 64204682
Product use issue 13.11 10.71 56 43931 151659 64303086
Product measured potency issue 13.07 10.71 5 43982 198 64454547
Carcinogenicity 12.90 10.71 4 43983 83 64454662
Traumatic haemothorax 12.82 10.71 6 43981 394 64454351
Tongue oedema 12.78 10.71 18 43969 5972 64448773
Hypersensitivity 12.76 10.71 80 43907 196372 64258373
Extrasystoles 12.74 10.71 19 43968 6639 64448106
Blood creatinine increased 12.66 10.71 145 43842 135637 64319108
Blood creatine phosphokinase MB increased 12.64 10.71 12 43975 2609 64452136
Disseminated aspergillosis 12.58 10.71 7 43980 661 64454084
Rhabdomyolysis 12.48 10.71 106 43881 91620 64363125
Anticoagulation drug level increased 12.47 10.71 7 43980 672 64454073
Stomatitis 12.46 10.71 36 43951 109569 64345176
Arrhythmia 12.46 10.71 70 43917 52874 64401871
Polyuria 12.45 10.71 27 43960 12616 64442129
Diffuse large B-cell lymphoma stage II 12.39 10.71 4 43983 95 64454650
Electrocardiogram abnormal 12.38 10.71 28 43959 13453 64441292
Loss of consciousness 12.32 10.71 155 43832 148210 64306535
Drop attacks 12.27 10.71 8 43979 1007 64453738
Rash 12.14 10.71 230 43757 458319 63996426
IIIrd nerve disorder 12.13 10.71 4 43983 102 64454643
Malaise 11.90 10.71 354 43633 395893 64058852
Bundle branch block left 11.73 10.71 23 43964 10011 64444734
Potentiating drug interaction 11.71 10.71 20 43967 7832 64446913
Cerebral salt-wasting syndrome 11.71 10.71 4 43983 114 64454631
Perioral dermatitis 11.64 10.71 5 43982 268 64454477
Alanine aminotransferase increased 11.60 10.71 52 43935 138979 64315766
Lower respiratory tract infection 11.56 10.71 30 43957 94584 64360161
Rectal haemorrhage 11.56 10.71 77 43910 61740 64393005
Mitral valve incompetence 11.53 10.71 41 43946 25497 64429248
Eosinophilia 11.51 10.71 54 43933 38022 64416723
Microcytic anaemia 11.51 10.71 15 43972 4623 64450122
Sedation 11.51 10.71 7 43980 41455 64413290
Toxic skin eruption 11.45 10.71 34 43953 19250 64435495
Thrombocytopenia 11.34 10.71 215 43772 223586 64231159
Tonic clonic movements 11.33 10.71 10 43977 1979 64452766
Intra-abdominal haematoma 11.29 10.71 11 43976 2468 64452277
Atrial tachycardia 11.25 10.71 13 43974 3546 64451199
Diarrhoea 11.21 10.71 601 43386 722103 63732642
Dry gangrene 11.19 10.71 7 43980 821 64453924
Lymphocyte count decreased 11.12 10.71 7 43980 40692 64414053
Hypertensive nephropathy 11.09 10.71 7 43980 834 64453911
Swelling 11.06 10.71 64 43923 160154 64294591
Malpositioned teeth 11.06 10.71 3 43984 38 64454707
Agoraphobia 11.04 10.71 6 43981 541 64454204
Osteonecrosis of jaw 10.98 10.71 55 43932 39770 64414975
Left ventricle outflow tract obstruction 10.89 10.71 5 43982 314 64454431
Urinary retention 10.89 10.71 64 43923 49137 64405608
Wrong schedule 10.85 10.71 5 43982 317 64454428
Vascular encephalopathy 10.79 10.71 6 43981 566 64454179
Condition aggravated 10.73 10.71 184 43803 372242 64082503

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C07AB12 CARDIOVASCULAR SYSTEM
BETA BLOCKING AGENTS
BETA BLOCKING AGENTS
Beta blocking agents, selective
ATC C07BB12 CARDIOVASCULAR SYSTEM
BETA BLOCKING AGENTS
BETA BLOCKING AGENTS AND THIAZIDES
Beta blocking agents, selective, and thiazides
ATC C07FB12 CARDIOVASCULAR SYSTEM
BETA BLOCKING AGENTS
BETA BLOCKING AGENTS, OTHER COMBINATIONS
Beta blocking agents and calcium channel blockers
ATC C09DX05 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS
Angiotensin II receptor blockers (ARBs), other combinations
FDA MoA N0000000161 Adrenergic beta-Antagonists
FDA EPC N0000175556 beta-Adrenergic Blocker
MeSH PA D018663 Adrenergic Agents
MeSH PA D000322 Adrenergic Agonists
MeSH PA D058665 Adrenergic beta-1 Receptor Agonists
MeSH PA D000318 Adrenergic beta-Agonists
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D014665 Vasodilator Agents
CHEBI has role CHEBI:35530 beta-adrenergic blockers
CHEBI has role CHEBI:35620 vasodilator agents
CHEBI has role CHEBI:35674 antihypertensive drugs
CHEBI has role CHEBI:176497 geroprotectors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Chronic heart failure off-label use 48447003
Atrial fibrillation off-label use 49436004 DOID:0060224
Angina pectoris off-label use 194828000
Myocardial Reinfarction Prevention off-label use
Bronchospasm contraindication 4386001
Complete atrioventricular block contraindication 27885002
Sick sinus syndrome contraindication 36083008 DOID:13884
Bradycardia contraindication 48867003
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Diabetes mellitus contraindication 73211009 DOID:9351
Cardiogenic shock contraindication 89138009
Second degree atrioventricular block contraindication 195042002
Decompensated cardiac failure contraindication 195111005
Disease of liver contraindication 235856003 DOID:409
Hypoglycemic disorder contraindication 237630007
Peripheral vascular disease contraindication 400047006




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.87 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 5MG BASE;80MG BYVALSON ALLERGAN N206302 June 3, 2016 DISCN TABLET ORAL 7838552 Oct. 4, 2027 METHOD OF TREATING HYPERTENSION

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Beta-1 adrenergic receptor GPCR ANTAGONIST Ki 8.50 WOMBAT-PK CHEMBL
Beta-2 adrenergic receptor GPCR ANTAGONIST Ki 7.50 WOMBAT-PK CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 8 WOMBAT-PK
Beta-3 adrenergic receptor GPCR ANTAGONIST Ki 5.66 IUPHAR

External reference:

IDSource
4027169 VUID
N0000179202 NUI
D05127 KEGG_DRUG
152520-56-4 SECONDARY_CAS_RN
4027169 VANDF
C0068475 UMLSCUI
CHEBI:64022 CHEBI
CHEMBL434394 ChEMBL_ID
CHEMBL1201731 ChEMBL_ID
D000068577 MESH_DESCRIPTOR_UI
DB04861 DRUGBANK_ID
71301 PUBCHEM_CID
7246 IUPHAR_LIGAND_ID
5969 INN_ID
030Y90569U UNII
236883 RXNORM
130026 MMSL
18486 MMSL
29969 MMSL
52690 MMSL
d05265 MMSL
007077 NDDF
007078 NDDF
318638009 SNOMEDCT_US
395808005 SNOMEDCT_US
734565001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Bystolic HUMAN PRESCRIPTION DRUG LABEL 1 0456-1402 TABLET 2.50 mg ORAL NDA 26 sections
Bystolic HUMAN PRESCRIPTION DRUG LABEL 1 0456-1402 TABLET 2.50 mg ORAL NDA 26 sections
Bystolic HUMAN PRESCRIPTION DRUG LABEL 1 0456-1405 TABLET 5 mg ORAL NDA 26 sections
Bystolic HUMAN PRESCRIPTION DRUG LABEL 1 0456-1405 TABLET 5 mg ORAL NDA 26 sections
Bystolic HUMAN PRESCRIPTION DRUG LABEL 1 0456-1410 TABLET 10 mg ORAL NDA 26 sections
Bystolic HUMAN PRESCRIPTION DRUG LABEL 1 0456-1410 TABLET 10 mg ORAL NDA 26 sections
Bystolic HUMAN PRESCRIPTION DRUG LABEL 1 0456-1420 TABLET 20 mg ORAL NDA 26 sections
Bystolic HUMAN PRESCRIPTION DRUG LABEL 1 0456-1420 TABLET 20 mg ORAL NDA 26 sections
nebivolol HUMAN PRESCRIPTION DRUG LABEL 1 0904-7189 TABLET 5 mg ORAL ANDA 24 sections
nebivolol HUMAN PRESCRIPTION DRUG LABEL 1 0904-7190 TABLET 10 mg ORAL ANDA 24 sections
nebivolol HUMAN PRESCRIPTION DRUG LABEL 1 0904-7225 TABLET 2.50 mg ORAL ANDA 24 sections
nebivolol HUMAN PRESCRIPTION DRUG LABEL 1 0904-7226 TABLET 20 mg ORAL ANDA 24 sections
nebivolol HUMAN PRESCRIPTION DRUG LABEL 1 13668-353 TABLET 2.50 mg ORAL ANDA 24 sections
nebivolol HUMAN PRESCRIPTION DRUG LABEL 1 13668-353 TABLET 2.50 mg ORAL ANDA 24 sections
nebivolol HUMAN PRESCRIPTION DRUG LABEL 1 13668-354 TABLET 5 mg ORAL ANDA 24 sections
nebivolol HUMAN PRESCRIPTION DRUG LABEL 1 13668-354 TABLET 5 mg ORAL ANDA 24 sections
nebivolol HUMAN PRESCRIPTION DRUG LABEL 1 13668-355 TABLET 10 mg ORAL ANDA 24 sections
nebivolol HUMAN PRESCRIPTION DRUG LABEL 1 13668-355 TABLET 10 mg ORAL ANDA 24 sections
nebivolol HUMAN PRESCRIPTION DRUG LABEL 1 13668-356 TABLET 20 mg ORAL ANDA 24 sections
nebivolol HUMAN PRESCRIPTION DRUG LABEL 1 13668-356 TABLET 20 mg ORAL ANDA 24 sections
Nebivolol Human Prescription Drug Label 1 27241-179 TABLET 2.50 mg ORAL ANDA 25 sections
Nebivolol Human Prescription Drug Label 1 27241-180 TABLET 5 mg ORAL ANDA 25 sections
Nebivolol Human Prescription Drug Label 1 27241-181 TABLET 10 mg ORAL ANDA 25 sections
Nebivolol Human Prescription Drug Label 1 27241-182 TABLET 20 mg ORAL ANDA 25 sections
Nebivolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 29300-375 TABLET 2.50 mg ORAL ANDA 23 sections
Nebivolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 29300-376 TABLET 5 mg ORAL ANDA 23 sections
Nebivolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 29300-377 TABLET 10 mg ORAL ANDA 23 sections
Nebivolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 29300-378 TABLET 20 mg ORAL ANDA 23 sections
Nebivolol HUMAN PRESCRIPTION DRUG LABEL 1 31722-585 TABLET 2.50 mg ORAL ANDA 24 sections
Nebivolol HUMAN PRESCRIPTION DRUG LABEL 1 31722-586 TABLET 5 mg ORAL ANDA 24 sections